These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8425442)

  • 1. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly.
    Ho PJ; Boyajy LD; Greenstein E; Barkan AL
    Dig Dis Sci; 1993 Feb; 38(2):309-15. PubMed ID: 8425442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study.
    Newman CB; Melmed S; Snyder PJ; Young WF; Boyajy LD; Levy R; Stewart WN; Klibanski A; Molitch ME; Gagel RF
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2768-75. PubMed ID: 7673422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    Quabbe HJ; Plöckinger U
    J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of the somatostatin analog SMS 201-995 (octreotide) in acromegaly. Effects of dose and frequency and long-term safety.
    Ho KY; Weissberger AJ; Marbach P; Lazarus L
    Ann Intern Med; 1990 Feb; 112(3):173-81. PubMed ID: 2404445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
    Vance ML; Harris AG
    Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide treatment of acromegaly. A randomized, multicenter study.
    Ezzat S; Snyder PJ; Young WF; Boyajy LD; Newman C; Klibanski A; Molitch ME; Boyd AE; Sheeler L; Cook DM
    Ann Intern Med; 1992 Nov; 117(9):711-8. PubMed ID: 1416572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective multicenter octreotide dose response study in the treatment of acromegaly.
    Ezzat S; Redelmeier DA; Gnehm M; Harris AG
    J Endocrinol Invest; 1995 May; 18(5):364-9. PubMed ID: 7594225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and tolerability of octreotide treatment in acromegaly.
    Christensen SE; Weeke J; Orskov H; Kaal A; Lund E; Jørgensen J; Harris AG
    Metabolism; 1992 Sep; 41(9 Suppl 2):44-50. PubMed ID: 1518433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of acromegaly with a long-acting analogue of somatostatin, octreotide.
    Page MD; Millward ME; Taylor A; Preece M; Hourihan M; Hall R; Scanlon MF
    Q J Med; 1990 Feb; 74(274):189-201. PubMed ID: 2111918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective clinical response to long term octreotide treatment, with reduced serum concentrations of growth hormone, insulin-like growth factor-I, and the amino-terminal propeptide of type III procollagen in acromegaly.
    Salmela PI; Juustila H; Pyhtinen J; Jokinen K; Alavaikko M; Ruokonen A
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1193-201. PubMed ID: 2180976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholelithiasis and acromegaly: therapeutic strategies.
    Montini M; Gianola D; Pagani MD; Pedroncelli A; Caldara R; Gherardi F; Bonelli M; Lancranjan I; Pagani G
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):401-6. PubMed ID: 8187305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion.
    Lim MJ; Barkan AL; Buda AJ
    Ann Intern Med; 1992 Nov; 117(9):719-26. PubMed ID: 1416573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of high-dose octreotide (Sandostatin) by continuous subcutaneous infusion for the treatment of acromegaly.
    White MC; James RA; Chatterjee S; Mother M; Hall K; Dunne MJ; Baister ER; Kendall-Taylor P
    Horm Res; 1990; 33 Suppl 1():13-8; discussion 18-9. PubMed ID: 1972690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of octreotide on biliary lipid composition and occurrence of cholesterol crystals in patients with acromegaly. A prospective study.
    Erlinger S; Chanson P; Dumont M; Ponsot P; Warnet A; Harris AG
    Dig Dis Sci; 1994 Nov; 39(11):2384-8. PubMed ID: 7956607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of octreotide, a somatostatin analog, on sleep apnea in patients with acromegaly.
    Grunstein RR; Ho KK; Sullivan CE
    Ann Intern Med; 1994 Oct; 121(7):478-83. PubMed ID: 8067645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycemic profile in patients with acromegaly treated with somatostatin analogue.
    Valea A; Carsote M; Ghervan C; Georgescu C
    J Med Life; 2015; 8 Spec Issue(Spec Issue):82-6. PubMed ID: 26361517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.